Phreesia, Inc. (NYSE:PHR – Get Free Report) has been given a consensus recommendation of “Hold” by the nineteen analysts that are currently covering the company, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, nine have issued a hold recommendation and nine have issued a buy recommendation on the company. The average 1-year target price among analysts that have issued ratings on the stock in the last year is $16.6471.
PHR has been the topic of several recent analyst reports. Piper Sandler lowered shares of Phreesia from an “overweight” rating to a “neutral” rating and set a $12.00 price objective on the stock. in a research note on Thursday, May 28th. Citizens Jmp reiterated a “market perform” rating on shares of Phreesia in a report on Wednesday, April 1st. DA Davidson reissued a “buy” rating and set a $14.00 price target on shares of Phreesia in a research report on Thursday, May 28th. JPMorgan Chase & Co. reissued a “neutral” rating and set a $16.00 price target (down from $24.00) on shares of Phreesia in a research report on Tuesday, March 31st. Finally, Weiss Ratings upgraded Phreesia from a “sell (d)” rating to a “sell (d+)” rating in a research note on Monday.
Get Our Latest Research Report on PHR
Institutional Investors Weigh In On Phreesia
Phreesia Price Performance
Shares of PHR opened at $10.22 on Monday. The company has a market cap of $631.53 million, a price-to-earnings ratio of 68.11 and a beta of 0.87. Phreesia has a 1-year low of $7.77 and a 1-year high of $32.76. The company’s fifty day simple moving average is $9.86 and its 200 day simple moving average is $11.14. The company has a current ratio of 1.76, a quick ratio of 1.76 and a debt-to-equity ratio of 0.41.
Phreesia (NYSE:PHR – Get Free Report) last posted its quarterly earnings results on Wednesday, May 27th. The company reported $0.05 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.02 by $0.03. The firm had revenue of $130.94 million for the quarter, compared to analyst estimates of $130.08 million. Phreesia had a net margin of 1.85% and a return on equity of 5.13%. The company’s quarterly revenue was up 12.9% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.07) earnings per share. On average, research analysts forecast that Phreesia will post 0.39 earnings per share for the current fiscal year.
Phreesia Company Profile
Phreesia, Inc (NYSE: PHR) is a provider of patient intake management solutions designed to streamline front-office workflows for healthcare organizations. The company’s cloud-based platform digitizes patient registration, appointment scheduling, insurance verification, consent documentation and payment collection through touchscreen kiosks, tablets and mobile devices. By replacing paper forms and manual processes, Phreesia enhances data accuracy, reduces administrative burden and improves the patient experience.
Founded in 2000 by Chaim Indig and headquartered in Burlington, Massachusetts, Phreesia offers a modular software suite that integrates with electronic medical record (EMR) and practice management systems.
See Also
- Five stocks we like better than Phreesia
- AMD and Cerbras Create A New Blueprint For Hardware
- Intel Earnings Reveal Whether the Chip Selloff Created a Buy
- CrowdStrike’s Cerebras Deal Puts Its AI Security Strategy to the Test
- Plugging In: How Kinder Morgan Powers Up Profits
Receive News & Ratings for Phreesia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Phreesia and related companies with MarketBeat.com's FREE daily email newsletter.
